Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Am J Med. 2010 Aug;123(8):764.e1–764.e9. doi: 10.1016/j.amjmed.2010.03.018

Figure 1.

Figure 1

Survival (months) among Patterns of Care Study subjects by age at diagnosis and imatinib utilization status. A- 20–59 years of age. B- 60–79 years of age. C- 80 and over years of age. These data indicate that elderly patients that did not receive imatinib fared more poorly compared to those that did. There was no significant difference in socioeconomic status or co-morbidities between those that received imatinib and those that did not.